^
Association details:
| Biomarker: | IRS2 amplification + KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | BMS-754807 (IGF-1R inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
Excerpt:
As IRS2 CNG is enriched in the sensitive cell lines (Fig. 1C), we next explored IRS2 CNG in relation to KRAS mutational status and found that IRS2 CNG was more significantly correlated with the drug sensitivity in KRAS-mutated colorectal cancer lines, that is, five of the six lines with IRS2 CNG were sensitive to BMS-754807...
DOI:
10.1158/1535-7163
